GCA
GILD icon

Gradient Capital Advisors’s Gilead Sciences GILD Stock Holding History

Gradient Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,315
Closed -$216K – 89
2019
Q1 		$216K Sell
3,315
-773
-19% -$51.4K 0.17% 83
2018
Q4 		$256K Sell
4,088
-548
-12% -$38.3K 0.22% 75
2018
Q3 		$358K Buy
4,636
+33
+0.7% +$2.49K 0.3% 66
2018
Q2 		$326K Buy
4,603
+446
+11% +$31.5K 0.3% 67
2018
Q1 		$313K Buy
4,157
+1
+0% +$79 0.31% 60
2017
Q4 		$298K Buy
+4,156
New +$316K 0.31% 61

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Gradient Capital Advisors's GILD Position: Q2 2019 in Review

Gradient Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2019, closing a stake of 3,315 shares — an estimated $216K sold.

Gradient Capital Advisors first reported a position in GILD in Q4 2017 and held it in 6 quarters. The position peaked at $358K in Q3 2018. 1,483 funds tracked by Wall St. Rank hold GILD as of Q2 2019.

  • Gradient Capital Advisors reported no remaining Gilead Sciences position as of Q2 2019 after selling out during the quarter.
  • Gradient Capital Advisors sold 3,315 Gilead Sciences shares in Q2 2019, an estimated $216K.
  • Gradient Capital Advisors first reported a position in Gilead Sciences in Q4 2017 and held it in 6 quarters.
  • Gradient Capital Advisors's Gilead Sciences position peaked at $358K in Q3 2018.
  • 1,483 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2019.

Based on Gradient Capital Advisors's 13F filing for Q2 2019, filed 16 Jul 2019.